Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

The biotech industry can be volatile even for relatively large companies. Amgen ( AMGN 1.00%), one of the more prominent names in the game, just reminded us all of that fact. On Nov. 26, the company's ...

Unless you have been living under a rock, you’ll know that anti-obesity GLP-1 drugs are the next big thing in pharma, with ...

From the "largest Christmas tree in the world," to almost three million lights raining down from the boughs of ...

Dr. Oz has extolled Ozempic’s promise for weight-loss. Now Medicare, which Trump wants Oz to oversee, may cover it.

Jaguar's rebranding marks a radical identity shift for the carmaker. One ad expert called it "bonkers." Others said it was a ...

It’ll be a busy December for dividend growth investors, with 25 companies announcing their annual increases. Check out the ...

Gov. Eric Holcomb said Clay Robbins' "humble service to our great state truly represents the very best of what it means to be ...

The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

Gov. Eric J. Holcomb honored Clay Robbins, chairman and CEO of Lilly Endowment, Inc., with the 2024 Sachem Award. A ceremony was held for friends, family and colleagues to celebrate Robbins as the ...

After 10 long years, the company that has developed a collagen biomaterial to help heal tissue is readying itself for its ...